ReviewVascular health and risk management2005
Lercanidipine in hypertension.
Review in Vascular health and risk management, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 60 citations in OpenAlex.
- Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.BMC cardiovascular disorders · 2016Trial
- Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake.European journal of clinical pharmacology · 2012Trial
- Superior palatability of crushed lercanidipine compared with amlodipine among children.British journal of clinical pharmacology · 2010Trial
- Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM.Journal of human hypertension · 2007Trial
- A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice.Vascular health and risk management · 2007Trial
- Real-World Adherence to Dihydropyridine Calcium-Channel Blockers: A Pharmacoepidemiologic Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
- Article
- Tolerability of Antihypertensive Medications: The Influence of Age.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024Article
- Lercanidipine alleviates doxorubicin-induced lung injury by regulating PERK/CHOP and Bax/Bcl 2/Cyt c pathways.Histochemistry and cell biology · 2023Article
- New Insights into the Nephroprotective Potential of Lercanidipine.International journal of molecular sciences · 2023Review
- Calcium channel blocker lercanidipine electrochemistry using a carbon black-modified glassy carbon electrode.Analytical and bioanalytical chemistry · 2020Article
- Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling.Molecular medicine reports · 2017Article
- Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Observational
- Determination of lercanidipine in human plasma by an improved UPLC-MS/MS method for a bioequivalence study.Journal of pharmaceutical analysis · 2016Article
- Lercanidipine/enalapril combination in the management of obesity-related hypertension.Integrated blood pressure control · 2016Review
- Development and validation of reversed phase high-performance liquid chromatography method for estimation of lercanidipine HCl in pure form and from nanosuspension formulation.Journal of basic and clinical pharmacy · 2015Article
- Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.Vascular health and risk management · 2008Review
- Lercanidipine in the Management of Hypertension: An Update.Journal of pharmacology & pharmacotherapeuticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lercanidipine is a lipophilic, dihydropyridine calcium antagonist with a long receptor half-life. Its slow onset of action helps to avoid reflex tachycardia associated with other dihydropyridines (DHPs). It produces even and sustained blood pressure lowering with once-daily dosing. It has equivalent antihypertensive efficacy to many other agents and is effective as initial monotherapy or in combination. Efficacy has been demonstrated in elderly as well as younger patients and also in the presence of other risk factors. Lercanidipine is well tolerated with DHP-associated adverse effects occurring early in treatment. The incidence of pedal edema and subsequent withdrawals has been found to be lower with lercanidipine than with amlodipine or nifedipine gastrointestinal transport system. Preclinical and preliminary clinical findings suggest lercanidipine may have beneficial effects on atherosclerosis and left ventricular hypertrophy. The efficacy and tolerability profiles of lercanidipine make it a suitable choice for treating hypertension in a wide range of affected patients.
Indexed as
Identifiers
17319103PMC1993952W1944683097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.